Drug Safety

, Volume 33, Issue 3, pp 213–221

Drug Utilization of Intrinsa® (Testosterone Patch) in England

Interim Analysis of a Prescription-Event Monitoring Study to Support Risk Management
  • Vicki Osborne
  • Lorna Hazell
  • Deborah Layton
  • Saad A.W. Shakir
Short Communication

Abstract

Background: Intrinsa® is a transdermal testosterone patch that is indicated for use in hypoactive sexual desire disorder (HSDD) in women who have undergone bilateral oophorectomy and hysterectomy (surgically-induced menopause) receiving concomitant oestrogen therapy.

Objective: To describe the utilization characteristics of the patients prescribed testosterone patch (Intrinsa®) based on an interim analysis of an ongoing Prescription-Event Monitoring study in England, and to assess, where possible, if the product is being used within the licensed therapeutic indication.

Methods: In this interim analysis, patients were identified from dispensed prescriptions that had been issued by general practitioners (GPs) for Intrinsa® from March 2007. ‘Green form’ questionnaires were sent to GPs 6 months following the date of the first prescription for Intrinsa® for each individual patient, requesting information including age, sex, start and stop dates of treatment (if stopped), prescribing indication and reasons for stopping. Additional questions were asked regarding the patient’s menopausal status and use of concomitant oestrogen therapy.

Results: The interim cohort consisted of 756 patients. The majority of patients were reported to be female (746 [98.7%]) with a median (interquartile range) age of 50 years (44–55 years). The most commonly reported indication was the licensed indication of HSDD in 580 patients (76.7%). Just under one-half of the patients (n=364 [48.1%]) were reported to have been hysterectomized and bilaterally oophorectomized (surgically-induced menopause) prior to starting Intrinsa®; 127 patients (16.8%) were naturally menopausal. For 222 patients (29.4%) the GP specified that the patient was not using concomitant oestrogen therapy. Overall, only 219 patients (29.0%) in the cohort were being prescribed Intrinsa® according to the manufacturer’s recommendations.

Conclusions: This study has highlighted that some clinicians are prescribing this product outside the recommended terms of the licence, with less than 30% of patients receiving Intrinsa® according to prescribing guidelines. All events experienced by these patients will be analysed to detect any possible adverse events from using Intrinsa® outside of the licensed therapeutic indication. The findings support the ongoing postmarketing risk management of the product.

References

  1. 1.
    Procter & Gamble. Intrinsa: summary of product characteristics, Procter & Gamble, 2007 [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/intrinsa/H-634-PI-en.pdf [Accessed 2010 Jan 29]
  2. 2.
    EMEA. Intrinsa: European public assessment report. EMA, 2006 [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/intrinsa/063406en6.pdf [Accessed 2010 Jan 29]
  3. 3.
    Braunstein GD, Sundwell DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women. Arch Intern Med 2005; 165: 1582–9PubMedCrossRefGoogle Scholar
  4. 4.
    Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for sexual desire in surgically menopausal women: a randomised trial. Obstet Gynecol 2005; 105: 944–52PubMedCrossRefGoogle Scholar
  5. 5.
    Davis SR, van der Morren MJ, van Lunsen RH, et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 2006; 13(3): 387–96PubMedCrossRefGoogle Scholar
  6. 6.
    Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343: 682–8PubMedCrossRefGoogle Scholar
  7. 7.
    Simon J, Braunstein G, Utian W, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005; 90: 5226–33PubMedCrossRefGoogle Scholar
  8. 8.
    Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008 Nov 6; 359(19): 2005–17PubMedCrossRefGoogle Scholar
  9. 9.
    Shifren JL, Davis SR, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 2006; 13(5): 770–9PubMedCrossRefGoogle Scholar
  10. 10.
    Martin K, Begaud B, Latry P, et al. Differences between clinical trials and postmarketing use1. Br J Clin Pharmacol 2004 Jan; 57(1): 86–92PubMedCrossRefGoogle Scholar
  11. 11.
    European Commission. Volume 9A of the rules governing medicinal products in the European Union: pharmacovigilance for medicinal products for human use. European Commission, 2008 [online]. Available from URL: http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-9/pdf/vol9a_09-2008.pdf [Accessed 2010 Jan 29]
  12. 12.
    Shakir SAW. Prescription-event monitoring. In: Mann RD, Andrews EB, editors. Pharmacovigilance. 2nd ed. Chichester: John Wiley & Sons Ltd, 2007: 307–16Google Scholar
  13. 13.
    Council for International Organizations of Medical Sciences (CIOMS), World Health Organisation (WHO). International ethical guidelines for biomedical research involving human subjects [online]. Available from URL: http://www.cioms.ch/frame_guidelines_nov_2002.htm [Accessed 2009 Dec 23]
  14. 14.
    Royal College of Physicians of London. Guidelines on the practice of ethics committees in medical research involving human subjects. 3rd ed. London: Royal College of Physicians of London, 1996Google Scholar
  15. 15.
    General Medical Council. Frequently asked questions. Supplement to ‘Confidentiality: Protecting and Providing Information’. London: General Medical Council, 2004: 9Google Scholar
  16. 16.
    GlaxoSmithKline. Andropatch: summary of product characteristics. GlaxoSmithKline, 2006 [online]. Available from URL: http://emc.medicines.org.uk/medicine/2019/SPC/Andropatch+2.5mg/ [Accessed 2010 Jan 29]
  17. 17.
    Shufelt C, Braunstein G. Safety of testosterone use in women. Maturitas 2009 May 20; 63(1): 63–6PubMedCrossRefGoogle Scholar
  18. 18.
    Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004; 108(3): 425–32PubMedCrossRefGoogle Scholar
  19. 19.
    US FDA. Intrinsa medical review. FDA, 2004 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4082B1_02_B-FDA-Intrinsa-Medical-Review.pdf [Accessed 2010 Jan 29]
  20. 20.
    Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 2002; 288(3): 321–33CrossRefGoogle Scholar
  21. 21.
    Panzer C, Guay A. Testosterone replacement therapy in naturally and surgically menopausal women. J Sex Med 2009; 6: 8–18PubMedCrossRefGoogle Scholar
  22. 22.
    Krapf J, Simon J. The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. Maturitas 2009; 63(3): 213–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Vicki Osborne
    • 1
    • 2
  • Lorna Hazell
    • 1
    • 2
  • Deborah Layton
    • 1
    • 2
  • Saad A.W. Shakir
    • 1
    • 2
  1. 1.Drug Safety Research UnitSouthamptonUK
  2. 2.School of Pharmacy and Biomedical Science, University of PortsmouthPortsmouthUK

Personalised recommendations